Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
Authors:
- Mary C. DunlayMDMary C. Dunlay
- Charles S. SweetCSCharles S. Sweet
- 1 April 1995
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 75 (12) , 793-795
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Pharmacodynamic Activity of Intravenous E-3174, an Angiotensin II Antagonist, in Patients With Essential HypertensionAmerican Journal of Hypertension, 1994
- Comparison of Angiotensin-Converting Enzyme Inhibition with Angiotensin II Receptor Antagonism in the Human ForearmJournal of Cardiovascular Pharmacology, 1993
- Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonistClinical Pharmacology & Therapeutics, 1992
- Pharmacology of Nonpeptide Angiotensin II Receptor AntagonistsAnnual Review of Pharmacology and Toxicology, 1992
- Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.Circulation, 1991